Introduction {#sec1}
============

Previous epidemiologic studies have suggested that allergic disease may be associated with either a reduced or an increased risk of cancer.[@bib1], [@bib2] Individuals with allergies have been found to have higher circulating levels of IgE, which is a product of T helper 2 (Th2) responses that are promoted in tissues by cytokines, such as IL4 and IL13. The *IL4* and *IL13* genes are located within the cytokine gene cluster on chromosome 5q31--31.1 They share a common IL4R chain on their receptors and are involved in the same signaling pathways.[@bib3] These cytokines may play a central role in allergies via stimulating IgE synthesis and reducing the production of pro-inflammatory cytokines by macrophages.[@bib2], [@bib4] Therefore, polymorphisms of the *IL4*, *IL13*, and *IL4R* genes may disrupt the balance of the cytokine network and may be involved in allergies and various cancers.[@bib5], [@bib6], [@bib7]

Gastrointestinal cancer is the leading cause of cancer-related death worldwide.[@bib8] Recently, several studies were conducted investigating the influence of these allergy-related polymorphisms on gastrointestinal cancer in different populations.[@bib9], [@bib10] Because the effect of genetic polymorphisms on cancer risk is small, a single study may be underpowered to detect a true association. Meta-analysis takes advantage of reduced random error in the observed effect estimates and produces a single estimate with enhanced precision.[@bib11] Some previous meta-analyses were conducted to investigate the association of *IL4* rs2243250 with either gastric cancer[@bib12] or colorectal cancer.[@bib9], [@bib10] However, the findings of these meta-analyses were inconclusive, and other polymorphisms of the IL4/IL13 pathway may help to clarify the role of polymorphisms in these genes in gastrointestinal carcinogenesis. Therefore, to gain more comprehensive knowledge of the associations of polymorphisms of the *IL4*, *IL13*, and *IL4R* genes with gastrointestinal cancer risk, we conducted a meta-analysis using six polymorphisms of these genes.

Methods {#sec2}
=======

Identification and eligibility of relevant studies {#sec2.1}
--------------------------------------------------

To identify all articles that explored the associations of six polymorphisms of *IL4*, *IL13*, and *IL4R* with gastrointestinal cancer risk, we conducted a literature search on PubMed and EMBASE from the year 2000 through February 3, 2016. Information on the selected polymorphisms is listed in [Table 1](#tbl1){ref-type="table"}. We used the following search terms: 1) "interleukin-4 (*IL-4* or *IL4*), interleukin-13 (*IL-13* or *IL13*), and interleukin-4R (*IL-4R* or *IL4R*)"; 2) "SNP, polymorphism, mutation, and variant"; 3) "cancer, tumor, carcinoma, and neoplasm"; and 4) "esophagus, gastric, colorectal, colon, rectal, hepatocellular, gallbladder, pancreatic, and gastrointestinal." To identify additional studies, we also screened the references of retrieved publications. Searches were limited to human studies and publications written in English. We did not consider abstracts or unpublished reports.

Studies included in this meta-analysis were required to meet the following criteria: 1) investigated the associations of *IL4*, *IL13*, and *IL4R* polymorphisms with gastrointestinal cancer risk; 2) used a case--control design; 3) provided genotype frequencies for cases and controls, so that odds ratios (ORs) with 95% confidence intervals (CIs) and a Hardy--Weinberg Equilibrium (HWE) could be calculated; and 4) featured a control population genotype distribution that did not deviate from HWE. Studies containing duplicated data were excluded. One study by El-Omar et al.[@bib13] presented genotype frequencies separately according to cancer type and was thus considered two studies in this meta-analysis.

Data extraction {#sec2.2}
---------------

Two investigators extracted the data independently and reached a consensus on all items. The following information was extracted from each article: author name, year of publication, country of study, source of controls, cancer type, genotype frequencies for cases and controls, and investigated polymorphisms.

Statistical analysis {#sec2.3}
--------------------

The strengths of the associations between the polymorphisms and gastrointestinal cancer risk were measured using ORs with corresponding 95% CIs. Forest plots were used to illustrate the results of the included studies. Five different ORs were calculated using the following models: 1) homozygote comparison, 2) heterozygote comparison, 3) dominant genetic model, 4) recessive genetic model, and 5) allele comparison. This meta-analysis reported unadjusted pooled results. Before analysis, the genotype frequencies of the polymorphisms were assessed for HWE using a Chi-squared test. A *p*-value \<0.01 was considered a significant deviation from HWE. The Q-statistic and *I*^*2*^ statistic were calculated to examine heterogeneity. The summary OR estimated for each study was calculated using either a fixed- or a random-effects model based on the Q-statistic.

Potential sources of heterogeneity were sought via subgroup analyses. For each genetic comparison, stratified analyses were performed according to cancer type, geographic location (Asia/non-Asia), and source of controls (hospital/population). Publication bias was investigated using a funnel plot, and funnel plot asymmetry was assessed using Egger\'s linear regression test.

All statistical analyses were performed using STATA software (version 11; Stata Corporation, College Station, TX, USA). Two-sided *p-*values \<0.05 were considered statistically significant.

Results {#sec3}
=======

Literature search and study characteristics {#sec3.1}
-------------------------------------------

According to our search criteria, a total of 279 articles were retrieved. After screening these articles based on title and abstract, 238 articles were excluded. We then evaluated the full text of the remaining 41 articles, and 15 articles were excluded for several reasons. A study flow chart depicting the literature search and selection is presented in [Fig. 1](#fig1){ref-type="fig"}. Ultimately, we found 26 articles describing 27 studies on the associations of the *IL4*, *IL13*, and *IL4R* polymorphisms with gastrointestinal cancer that matched our inclusion criteria: *IL4* rs2243250 (16 studies; 3783 cases/4895 controls) and rs2070874 (6 studies; 2202 cases/3388 controls), *IL13* rs1800925 (5 studies; 1054 cases/1384 controls) and rs20541 (3 studies; 2162 cases/2568 controls), and *IL4R* rs1805010 (5 studies; 1215 cases/2004 controls) and rs1801275 (6 studies; 1013 cases/1065 controls).

The allele frequency of each polymorphism in the controls is listed in [Table 1](#tbl1){ref-type="table"}. The frequency of the T allele in *IL4* rs2243250 and rs2070874 was higher in the controls from Asian countries than in the controls from non-Asian countries (0.78 *vs.* 0.17 for rs2243250; 0.80 vs. 0.13 for rs2070874). [Table 2](#tbl2){ref-type="table"} presents the characteristics of the studies included in the meta-analysis. The studies were conducted using either population or hospital controls in various countries and investigated gastrointestinal cancers, including esophageal,[@bib13], [@bib14] gastric,[@bib13], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] colorectal,[@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32] hepatocellular,[@bib33], [@bib34] and pancreatic cancer.[@bib35], [@bib36], [@bib37]

Outcome from eligible studies {#sec3.2}
-----------------------------

*IL4* rs2243250 was not associated with gastrointestinal cancer risk for any of the genetic models and subgroup analyses ([Fig. 2](#fig2){ref-type="fig"} and [eTable 1](#appsec1){ref-type="sec"}). For *IL4* rs2070874, an increased risk was observed for T allele carriers (OR 1.11; 95% CI, 1.00--1.24 for T allele *vs*. C allele), and this association was significant in studies conducted in studies outside of Asia (OR 1.28; 95% CI, 1.03--1.58 for T allele *vs*. C allele) and was significant in studies investigating the association with gastric cancer (OR 1.17; 95% CI, 1.03--1.34 for T allele *vs*. C allele) ([Fig. 3](#fig3){ref-type="fig"} and [eTable 1](#appsec1){ref-type="sec"}). Both *IL13* rs20541 and rs1800925 were not associated with gastrointestinal cancer risk for any of the genetic models and subgroup analyses ([eTable 2](#appsec1){ref-type="sec"}). For *IL4R* rs1801275, heterozygote seems to be associated with a reduced risk of gastrointestinal cancer (OR 0.79; 95% CI, 0.65--0.96 for AG *vs*. AA: OR 0.82; 95% CI, 0.68--0.99 for GG/AG *vs*. AA) ([Fig. 4](#fig4){ref-type="fig"} and [eTable 3](#appsec1){ref-type="sec"}). However, *IL4R* rs1805010 was not associated with gastrointestinal cancer risk for any of the genetic models and subgroup analyses ([eTable 3](#appsec1){ref-type="sec"}).

Publication bias {#sec3.3}
----------------

Begg\'s funnel plot and Egger\'s test were performed to evaluate publication bias. The funnel plot of the selected studies showed significant symmetry, and the results of Egger\'s test indicated no significant publication bias (data not shown).

Discussion {#sec4}
==========

To derive more precise conclusions about the associations between allergy-related polymorphisms and gastrointestinal cancer risk, we performed a comprehensive meta-analysis of 27 case--control studies that included six polymorphisms of *IL4*, *IL13*, and *IL4R* genes. In this meta-analysis, an increased risk of gastrointestinal cancer was observed in those carrying the *IL4* rs2070874 T variant, whereas a reduced risk of gastrointestinal cancer was observed in those who were heterozygous for *IL4R* rs1801275.

The role of *IL4* rs2243250 in carcinogenesis has been investigated in many studies, but the findings are still inconclusive. In previous meta-analyses, Sun et al.[@bib12] reported a possible positive association between gastric cancer and the *IL4* rs2243250 T allele in Caucasians, but Li et al.[@bib10] and Wu et al.[@bib9] reported no association between IL4 rs2243250 and colorectal cancer risk. We also found no association of the *IL4* rs2243250 T allele with gastrointestinal cancer. However, a positive association between *IL4* rs2070874 T allele carriers and gastrointestinal cancer risk was observed. Crusius et al.[@bib18] studied a Caucasian population from 10 European countries and found a significant positive association for *IL4* rs2070874 T allele carriers. Our findings may support the role of this polymorphism in gastrointestinal carcinogenesis. However, we also found a reduced risk of gastrointestinal cancer in *IL4R* rs1801275 heterozygote carriers, which is in contrast to the findings for *IL4* rs2070874. This may be a chance finding, but the underlying mechanisms should be investigated further.

Polymorphisms of *IL4*, *IL13*, and *IL4R* are suggested to affect the level of IgE because these polymorphisms are associated with greater expression of these genes and cytokines.[@bib5], [@bib38], [@bib39] A meta-analysis by Wang et al.[@bib40] indicated that variants of *IL4* (rs2243250 and rs2070874) and *IL13* (rs1800925 and rs20541) were associated with an increased risk of asthma. In *in vitro* experiments, higher total serum IgE levels were observed in T allele carriers of *IL4* rs2243250 and rs2070874 and *IL13* rs1800925 and rs20541.[@bib41] Rosenwasser et al.[@bib39] reported that four single nucleotide polymorphisms tested in the IL4/IL13 pathway are suspected of altering the function of specific genes. Several mechanisms have been proposed to explain the role of IgE in carcinogenesis. It is possible that the capacity for Th2 responses to simultaneously promote and suppress natural surveillance may lead to inconsistent findings.[@bib42] High IgE reflects immune hyper-responsiveness, leading to the detection and eradication of dysregulated cells.[@bib2] However, Th2 cytokines, such as IL4 and IL13, suppress interferon-γ associated inflammatory Th1 and cytolytic responses. Thus, allergies may be positively associated with cancer.[@bib42]

Several other factors may affect the association between the investigated polymorphisms and gastrointestinal cancer risk. In this meta-analysis, the positive association between *IL4* rs2070874 T allele carriers and gastrointestinal cancer risk was stronger in studies conducted outside of Asia. The T allele frequency of *IL4* rs2243250 and rs2070874 was very different between Asians and non-Asians; differences in the *IL4* genetic background among ethnicities may explain the different roles of this gene in the same disease.[@bib33] In addition to this, the positive association with *IL4* rs2070874 T allele carriers was only significant in studies investigating the association with gastric cancer, suggesting that the role of this polymorphism in carcinogenesis could differ by cancer type. Of the six included studies that evaluated this polymorphism, only a study by Crusius et al.[@bib18] found a significant positive association for *IL4* rs2070874 T allele carriers, particularly among patients with non-cardia intestinal type gastric cancer infected with *H. pylori* in a Caucasian population. However, other studies showed no association. Even though differences in study design (e.g., sample size and ethnicity) may affect the inconsistent findings between studies, the intrinsic heterogeneity of gastrointestinal carcinogenesis, sub-classified by anatomic location and histologic changes, should also be considered when interpreting the findings.[@bib43] Finally, different environmental and lifestyle factors can interact with gene polymorphisms and strengthen or weaken the effect of the studied polymorphisms.[@bib40] Gene--gene interactions may also contribute to the complexity of genetic diseases.[@bib5] An analysis of genotype data from a large population of German children showed that when polymorphisms of *IL4*, *IL13*, *IL4R*, and *STAT6* were combined, the risk of high serum IgE levels increased by 10.8 times, and the risk of the development of asthma increased by 16.8 times compared with the effect of any individual polymorphism.[@bib41]

The present findings should be interpreted with caution because of some limitations of the meta-analysis. First, the quality of a meta-analysis depends on the quality of the original studies. In our case, all studies were retrospective case--control studies, some of which involved small sample sizes and used hospital-based controls. Second, we evaluated only two polymorphisms per gene, which may limit our ability to elucidate the role of related cytokines in gastrointestinal cancer risk. Third, some inevitable publication bias may exist because only published studies were retrieved, although the funnel plot and Egger\'s test did not reveal significant publication bias. Finally, the numbers of published studies collected in our analysis were not large enough for comprehensive analysis. Considering all of these factors, future studies should be designed to overcome these limitations.

In conclusion, we investigated the role of six potentially functional variants of the *IL4*, *IL13*, and *IL4R* genes in gastrointestinal cancer risk based on the hypothesis that total serum IgE levels may affect carcinogenesis. The results of this meta-analysis indicated that some of these cytokine polymorphisms may affect susceptibility to gastrointestinal cancer. Therefore, case--control studies with larger sample sizes and multi-ethnic groups are needed to further investigate these associations in detail. Moreover, detailed gene--gene and gene--environment interaction data are needed for a comprehensive understanding of the association between the studied polymorphisms and cancer risk.
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###### 

Primary information for the six polymorphisms included in the meta-analysis.

Table 1

  Gene        Function and pathway                    Ch. location       rs number           Location   Trivial name       Base change   MAF in controls, mean[a](#tbl1fna){ref-type="table-fn"}   
  ----------- --------------------------------------- ------------------ ------------------- ---------- ------------------ ------------- --------------------------------------------------------- ------
  *IL4*       Th2 differentiation and IgE induction   5q31.1             rs2243250           Promoter   C-590T             C \> T        0.78                                                      0.17
  rs2070874   5′UTR                                   C-33T              C \> T              0.80       0.13                                                                                       
  *IL13*      Th2 effector functions                  5q31               rs1800925           Promoter   C-1112T, C-1055T   C \> T        0.17                                                      0.17
              rs20541                                 Exon4              G2044A, Arg130Gln   C \> T     0.19               0.40                                                                    
  *IL4R*      α-chain of the IL4 and IL13 receptors   16p12.1-p11.2      rs1805010           Exon5      Ile50Val, I75V     A \> G        0.57                                                      0.45
  rs1801275   Exon12                                  Gln551Arg, Q675R   A \> G              0.17       0.19                                                                                       

Ch, chromosome; IL4, interleukin-4; IL13, interleukin-13; IL4R, interleukin-4 receptor; MAF, minor allele frequency.

Frequency of variant allele in controls in studies included in this meta-analysis.

###### 

Characteristics of the studies included in the meta-analysis.

Table 2

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author (year)              Country        Cancer type      Number of cases/controls   Source of control   SNPs
  -------------------------------- -------------- ---------------- -------------------------- ------------------- --------------------------------------------
  El-Omar (2003)[@bib13]           USA            Gastric          112/209                    P                   rs2243250

  El-Omar (2003)[@bib13]           USA            Esophageal       90/209                     P                   rs2243250

  Wu (2003)[@bib15]                Taiwan         Gastric          220/230                    H                   rs2243250, rs1805010, rs1801275

  Lai (2005)[@bib16]               China          Gastric          123/162                    P                   rs2243250

  Cozar (2007)[@bib24]             Spain          Colorectal       96/174                     H                   rs2243250

  Garcia-Gonzalez (2007)[@bib17]   Spain          Gastric          404/404                    P                   rs2243250

  Landi (2007)[@bib25]             Spain          Colorectal       281/269                    H                   rs2243250, rs2070874, rs1805010, rs1801275

  Olson (2007)[@bib36]             USA            Pancreatic       405/212                    H                   rs2243250, rs1801275

  Yannopoulos (2007)[@bib26]       Greece         Colorectal       95/108                     P                   rs2243250

  Crusius (2008)[@bib18]           10 European\   Gastric          244/1160                   P                   rs2243250, rs2070874, rs1805010
                                   countries                                                                      

  Suchy (2008)[@bib27]             Poland         Colorectal       350/350                    H                   rs2243250

  Wilkening (2008)[@bib28]         Sweden         Colorectal       304/582                    P                   rs2243250

  Zambon (2008)[@bib19]            Italy          Gastric          142/171                    H                   rs2243250, rs1805010, rs1801275

  Ando (2009)[@bib20]              Japan          Gastric          330/190                    H                   rs2243250, rs1805010

  Ko (2009)[@bib21]                Korea          Gastric          81/324                     P                   rs2243250, rs2070874

  Scola (2009)[@bib35]             Italy          Pancreatic       48/131                     H                   rs1801275, rs1800925

  Wu (2009)[@bib44]                China          Gastric          1042/1099                  P                   rs2070874

  Lee (2010)[@bib29]               Korea          Colorectal       170/130                    P                   rs1801275

  Sainz (2012)[@bib30]             Sweden         Colorectal       1789/1771                  P                   rs20541

  Walczak (2012)[@bib31]           Poland         Colorectal       191/205                    P                   rs1800925

  Sun (2013)[@bib14]               China          Esophageal       365/369                    H                   rs1800925

  Lu (2014)[@bib33]                China          Hepatocellular   154/170                    P                   rs2243250, rs2070874

  Pan (2014)[@bib22]               China          Gastric          308/308                    P                   rs2243250

  Yu (2014)[@bib32]                China          Colorectal       299/296                    P                   rs2070874

  Cotterchio (2015)[@bib37]        Canada         Pancreatic       172/566                    P                   rs20541

  Deng (2015)[@bib34]              China          Hepatocellular   192/192                    P                   rs1800925, rs20541

  Yin (2015)[@bib23]               China          Gastric          234/465                    H                   rs1800925
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

H, hospital; P, population.
